Oaktree Acquisition Corp. III

Company Overview

Business Model: Oaktree Acquisition Corp. III Life Sciences is a blank check company, or Special Purpose Acquisition Company (SPAC), formed to effect a business combination with a target company. It has no operating history or revenues to date and does not expect to generate operating revenues until the consummation of an initial business combination. The company intends to focus on North American, British, or European companies within the biopharmaceutical, medical devices, diagnostics, and specialized healthcare services sectors. The target enterprise value range for a business combination is $500 million to $1.5 billion.

Market Position: As a blank check company, Oaktree Acquisition Corp. III Life Sciences' market position is primarily defined by its sponsor, Oaktree Capital Management, L.P. (Oaktree). Oaktree, founded in 1995, had approximately $202 billion in assets under management (AUM) as of December 31, 2024, including $18.3 billion in private equity strategies and over $45.6 billion in opportunities funds and distressed strategies. Oaktree's Life Sciences investment platform, co-led by Chairman Dr. Aman Kumar, has committed approximately $5 billion across 51 life sciences investments since 2013, with no realized losses. Historically, 65% of these investments were in US companies, 21% in European companies, and about two-thirds in biopharma. Oaktree's prior SPACs, Oaktree Acquisition Corp. and Oaktree Acquisition Corp. II, completed business combinations with Hims, Inc. and Alvotech Holdings S.A., respectively, generating a combined equity return of approximately 102% since their respective IPOs as of December 31, 2024.

Recent Strategic Developments: Oaktree Acquisition Corp. III Life Sciences was incorporated on June 28, 2024. Its units (OACCU) began trading on The Nasdaq Stock Market LLC on October 24, 2024, followed by separate trading of its Class A ordinary shares (OACC) and redeemable warrants (OACCW) on December 16, 2024. As of December 31, 2024, the aggregate market value of ordinary shares held by non-affiliates was approximately $191,222,329. The company is actively seeking an initial business combination.

Geographic Footprint: The company's principal executive offices are located in Los Angeles, California, and it is incorporated in the Cayman Islands. Its search for a business combination target is focused on North American, British, or European companies.

Financial Performance

Revenue Analysis

Profitability Metrics:

• Gross Margin: Not meaningful due to no operating revenue.
• Operating Margin: Not meaningful due to no operating revenue.
• Net Margin: Not meaningful due to no operating revenue, as net income is primarily driven by interest earned on cash held in the Trust Account.

Investment in Growth:

• R&D Expenditure: $0
• Capital Expenditures: $0
• Strategic Investments: Not applicable for a blank check company without operations.

Capital Allocation Strategy

Shareholder Returns:

• Share Repurchases: $0
• Dividend Payments: $0
• Dividend Yield: 0%
• Future Capital Return Commitments: The company has no specific commitments for future capital returns. Public shares are subject to redemption if a business combination is not completed within 24 months from the IPO closing, or if shareholders elect to redeem their shares in connection with a business combination.

Balance Sheet Position (as of December 31, 2024):

• Cash and Equivalents: $1,357,044
• Total Debt: $11,824 (Promissory note - related party)
• Net Cash Position: $1,345,220
• Credit Rating: Not disclosed.
• Debt Maturity Profile: The promissory note from a related party for $11,824 is due on demand.

Cash Flow Generation (for the period from June 28, 2024 (inception) through December 31, 2024):

• Operating Cash Flow: $(89,687)
• Free Cash Flow: Not meaningful for a blank check company.
• Cash Conversion Metrics: Not meaningful for a blank check company.

Additional Capital Allocation Details: The sponsor, Oaktree Acquisition Holdings III LS, LLC, paid $25,000 for 4,799,758 Class B ordinary shares. The sponsor also purchased 583,981 private placement units for $5,839,810. The company may obtain up to $1,500,000 in working capital loans from the sponsor or its affiliates, convertible into private placement units at $10.00 per unit, though no such borrowings were outstanding as of December 31, 2024. Permitted withdrawals from the trust account are limited to $250,000 annually (plus rollover) for working capital or taxes. The sponsor and management team have waived redemption rights for their founder shares and private placement shares. Underwriters are entitled to $6,719,660 in deferred underwriting commissions, payable upon the completion of a business combination. The company pays the sponsor $25,000 per month for office space, secretarial, and administrative services, with $55,833 incurred for these services from October 23, 2024, through December 31, 2024.

Competitive Intelligence

Market Structure & Dynamics

Industry Characteristics: Oaktree Acquisition Corp. III Life Sciences operates within the Special Purpose Acquisition Company (SPAC) market, specifically targeting the biopharmaceutical, medical devices, diagnostics, and specialized healthcare services sectors. This market is characterized by a competitive landscape where multiple blank check companies vie to identify and acquire suitable private companies within a defined timeframe.

Competitive Positioning Matrix:

Direct Competitors

Primary Competitors: The company's primary competitors are other blank check companies and traditional private equity firms seeking to acquire businesses in the life sciences and healthcare sectors within North America, Britain, and Europe.

Competitive Response Strategy: The company's strategy to maintain a competitive advantage in sourcing and executing a business combination relies on the experience and network of its sponsor, Oaktree Capital Management, L.P., and its management team, particularly their expertise in the life sciences sector and prior SPAC success.

Risk Assessment Framework

Strategic & Market Risks

Market Dynamics: As a blank check company, Oaktree Acquisition Corp. III Life Sciences has no operating history or revenues. The company faces a 24-month deadline from its initial public offering to complete a business combination, which may grant target businesses leverage in negotiations. Technology Disruption: While not directly applicable to the SPAC itself, the company's focus on the life sciences sector means potential target businesses may be exposed to risks of rapid technological change and disruption.

Operational & Execution Risks

Sponsor Dependency: The sponsor, Oaktree Acquisition Holdings III LS, LLC, controls approximately 20% of the ordinary shares (as-converted, excluding private placement shares) and has the right to elect all directors prior to a business combination, which could influence strategic decisions. Dilution Risk: The nominal purchase price paid by the sponsor for founder shares ($0.005 per share) may result in significant dilution for public shareholders. The sponsor's total investment of $5,864,810 could be recouped if Class A ordinary shares were as low as approximately $1.09 per share, indicating a low-cost basis for the sponsor's equity.

Financial & Regulatory Risks

Market & Financial Risks: The company's ability to complete a business combination and the value of its shares could be affected by broader global economic conditions and geopolitical events, including the COVID-19 pandemic, the Russia-Ukraine conflict, and the Israel-Hamas conflict. Regulatory & Compliance Risks:

• 2024 SPAC Rules: The company is subject to the 2024 SPAC Rules, effective July 1, 2024, which impose additional disclosure requirements and may increase liability for the company and its directors and officers.
• PFIC Status: The company may be deemed a passive foreign investment company (PFIC) for U.S. federal income tax purposes, which could have adverse tax consequences for U.S. investors.
• Excise Tax: The 1% U.S. federal excise tax on stock buybacks, effective January 1, 2023, could apply to redemptions of shares if the company becomes a "covered corporation," although proposed Treasury regulations exempt complete liquidations under certain sections of the Code.
• Cayman Islands Incorporation: The company's incorporation in the Cayman Islands may limit the ability of U.S. investors to protect their interests in U.S. federal courts. A tax exemption undertaking from the Cayman Islands government is in place for 30 years from July 5, 2024.

Geopolitical & External Risks

Geopolitical Exposure: The company's operations and potential business combination could be impacted by global geopolitical instability, including the ongoing effects of the COVID-19 pandemic, the Russia-Ukraine conflict, and the Israel-Hamas conflict.

Leadership & Governance

Executive Leadership Team

Leadership Continuity: The board of directors is divided into three classes with three-year terms, providing for staggered leadership. Board Composition: Paul Meister and Alvin Shih are independent directors. They both serve on the audit, nominating, and compensation committees. Paul Meister is designated as an "audit committee financial expert."

Regulatory Environment & Compliance

Regulatory Framework:

• Industry-Specific Regulations: As a blank check company, Oaktree Acquisition Corp. III Life Sciences is subject to specific regulations governing SPACs, including the 2024 SPAC Rules which became effective July 1, 2024. These rules impose additional disclosure requirements and may increase liability for the company.
• International Compliance: The company is incorporated in the Cayman Islands and operates under its legal framework. It has a tax exemption undertaking from the Cayman Islands government for 30 years from July 5, 2024.
• Trade & Export Controls: Not specifically detailed in the filing.

Legal Proceedings:

• No material litigation is pending or contemplated against the company.
• The warrant agreement designates New York courts as the exclusive forum for certain disputes, which may limit the ability of warrant holders to bring claims in other jurisdictions.

Tax Strategy & Considerations

Tax Profile:

• Effective Tax Rate: Not meaningful for a shell company whose income is primarily derived from interest earned on its trust account.
• Geographic Tax Planning: The company is incorporated in the Cayman Islands and benefits from a 30-year tax exemption undertaking from the Cayman Islands government, effective July 5, 2024.
• Tax Reform Impact: The company may be subject to the 1% U.S. federal excise tax on stock buybacks, effective January 1, 2023, if it becomes a "covered corporation" and engages in redemptions, although proposed Treasury regulations may exempt complete liquidations. Additionally, the company may be deemed a passive foreign investment company (PFIC), which could have adverse U.S. federal income tax consequences for its U.S. investors.